CPMC-R.K. DAVIES MEDICAL CENTER
- Type
- Teaching hospital
- Where
- SAN FRANCISCO, CA
- Medicare CCN
- 050008
- Received
- $1,407,669 in 178 records, 2025 ($78,409 general, $1,329,260 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 15 | $78,409 |
| 2025 | Research payment | 163 | $1,329,260 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | 59 | $293,894 | 2025 |
| Edwards Lifesciences Corporation | 25 | $272,450 | 2025 |
| Abbott Laboratories | 13 | $135,867 | 2025 |
| Boston Scientific Corporation | 6 | $126,117 | 2025 |
| Eli Lilly and Company | 4 | $118,233 | 2025 |
| GENZYME CORPORATION | 4 | $99,769 | 2025 |
| Gilead Sciences, Inc. | 11 | $70,173 | 2025 |
| Stryker Corporation | 13 | $42,489 | 2025 |
| Iovance Biotherapeutics, Inc. | 1 | $38,980 | 2025 |
| ModernaTX, Inc. | 6 | $37,972 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 4 | $29,585 | 2025 |
| Jenavalve Technology, Inc. | 1 | $27,625 | 2025 |
| Celgene Corporation | 2 | $25,625 | 2025 |
| Enterra Medical, Inc. | 4 | $20,395 | 2025 |
| UCB SA | 1 | $19,981 | 2025 |
| Genentech, Inc. | 1 | $14,304 | 2025 |
| GT Medical Technologies, Inc | 19 | $12,946 | 2025 |
| Biogen, Inc. | 2 | $11,671 | 2025 |
| KARL STORZ Endoscopy-America | 1 | $8,708 | 2025 |
| Carl Zeiss Meditec USA, Inc. | 1 | $877 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 163 | $1,329,260 |
| Long term medical supply or device loan | 13 | $49,906 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $27,625 |
| Food and Beverage | 1 | $877 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Stryker Corporation | $5,360 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $5,360 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $5,360 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,808 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,716 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,477 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,477 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,000 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,000 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,000 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,596 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-19 | Edwards Lifesciences Corporation | $1,937 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-12-18 | Carl Zeiss Meditec USA, Inc. | $877 | Food and Beverage | In-kind items and services | Retina Workplace Device, Software | 2025 | |
| 2025-12-16 | Boston Scientific Corporation | $2,599 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | SIMPLAAFY | 2025 |
| 2025-12-11 | Edwards Lifesciences Corporation | $7,511 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2025 | |
| 2025-12-10 | Edwards Lifesciences Corporation | $25,304 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-12-09 | Boston Scientific Corporation | $3,851 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT PAS | 2025 |
| 2025-12-08 | Alnylam Pharmaceuticals Inc. | $103 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-05 | Edwards Lifesciences Corporation | $44,420 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $1,733 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-30 | Enterra Medical, Inc. | $283 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-11-28 | Edwards Lifesciences Corporation | $2,474 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2025 | |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | $17,048 | Research payment | Cash or cash equivalent | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $16,072 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $12,249 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $2,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $1,733 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-18 | Boston Scientific Corporation | $30,311 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT PAS | 2025 |
| 2025-11-05 | Abbott Laboratories | $11,208 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-11-04 | Boston Scientific Corporation | $32,492 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT LTO | 2025 |
| 2025-11-03 | Abbott Laboratories | $30,282 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-11-03 | Gilead Sciences, Inc. | $2,624 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-10-31 | Enterra Medical, Inc. | $2,250 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-10-30 | Abbott Laboratories | $1,340 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-10-28 | Boston Scientific Corporation | $55,539 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT PAS | 2025 |
| 2025-10-28 | Gilead Sciences, Inc. | $3,301 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2025 |
| 2025-10-24 | ModernaTX, Inc. | $11,955 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-10-22 | Celgene Corporation | $23,750 | Research payment | Cash or cash equivalent | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $16,072 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,271 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,271 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,271 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $12,249 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $12,249 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $2,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $2,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $1,770 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $1,579 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $1,548 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $1,080 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $540 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-15 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-10-09 | Edwards Lifesciences Corporation | $176 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-10-02 | Edwards Lifesciences Corporation | $17,382 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-01 | Enterra Medical, Inc. | $17,250 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-10-01 | Edwards Lifesciences Corporation | $7,133 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-10-01 | Gilead Sciences, Inc. | $1,250 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-10-01 | Gilead Sciences, Inc. | $1,165 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-10-01 | Edwards Lifesciences Corporation | $405 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2025 | |
| 2025-09-30 | Edwards Lifesciences Corporation | $41,022 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2025 | |
| 2025-09-30 | Enterra Medical, Inc. | $611 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-09-23 | Gilead Sciences, Inc. | $1,310 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-09-18 | Iovance Biotherapeutics, Inc. | $38,980 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | NCT02360579 | 2025 |
| 2025-09-18 | Edwards Lifesciences Corporation | $8,189 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2025 | |
| 2025-09-16 | Jenavalve Technology, Inc. | $27,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-12 | Gilead Sciences, Inc. | $11,645 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-09-03 | Alnylam Pharmaceuticals Inc. | $10,000 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-09-03 | Alnylam Pharmaceuticals Inc. | $2,540 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-21 | Edwards Lifesciences Corporation | $1,946 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-08-19 | Gilead Sciences, Inc. | $7,903 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-08-15 | Alnylam Pharmaceuticals Inc. | $206 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-15 | Alnylam Pharmaceuticals Inc. | $103 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | $3,800 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-13 | Abbott Laboratories | $2,121 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-08-13 | Abbott Laboratories | $2,092 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | $1,538 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-13 | GT Medical Technologies, Inc | $985 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $985 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $729 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $627 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $627 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $499 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $499 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $499 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $465 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-13 | GT Medical Technologies, Inc | $465 | Research payment | Cash or cash equivalent | GammaTile Device, CNS | GTM-101 | 2025 |
| 2025-08-11 | GENZYME CORPORATION | $39,040 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-08-01 | ModernaTX, Inc. | $16,080 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-08-01 | Alnylam Pharmaceuticals Inc. | $4,579 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-01 | Alnylam Pharmaceuticals Inc. | $236 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-01 | Alnylam Pharmaceuticals Inc. | $206 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-08-01 | Alnylam Pharmaceuticals Inc. | $93 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-07-31 | Edwards Lifesciences Corporation | $34,344 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-07-31 | Abbott Laboratories | $2,810 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-07-23 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-07-22 | Gilead Sciences, Inc. | $26,670 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-07-22 | Edwards Lifesciences Corporation | $4,413 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-07-15 | Gilead Sciences, Inc. | $3,630 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2025 |
| 2025-07-02 | Alnylam Pharmaceuticals Inc. | $12,249 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-07-02 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-06-26 | Edwards Lifesciences Corporation | $25,203 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-06-23 | Alnylam Pharmaceuticals Inc. | $2,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-06-23 | Alnylam Pharmaceuticals Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-06-23 | Alnylam Pharmaceuticals Inc. | $436 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-06-02 | UCB SA | $19,981 | Research payment | Cash or cash equivalent | Zilbrysq Biological, Neurology | Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | 2025 |
| 2025-05-28 | Celgene Corporation | $1,875 | Research payment | Cash or cash equivalent | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2025 | |
| 2025-05-27 | Boston Scientific Corporation | $1,324 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2025 |
| 2025-05-12 | Abbott Laboratories | $5,760 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-05-06 | Gilead Sciences, Inc. | $9,574 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2025 |
| 2025-05-02 | Alnylam Pharmaceuticals Inc. | $15,271 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-05-02 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-05-02 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-05-02 | ModernaTX, Inc. | $4,295 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-05-02 | Alnylam Pharmaceuticals Inc. | $2,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-05-02 | Alnylam Pharmaceuticals Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-04-23 | Abbott Laboratories | $12,787 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-04-23 | ModernaTX, Inc. | $729 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-04-14 | Genentech, Inc. | $14,304 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2025 |
| 2025-04-11 | Stryker Corporation | $1,291 | Research payment | Cash or cash equivalent | THE CITADEL EMBOLIZATION DEVICE FEASIBILITY STUDY | 2025 | |
| 2025-04-11 | ModernaTX, Inc. | $1,000 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-04-10 | KARL STORZ Endoscopy-America | $8,708 | Long term medical supply or device loan | In-kind items and services | n.a. Device, OR1 | 2025 | |
| 2025-04-08 | Eli Lilly and Company | $4,812 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 | |
| 2025-04-03 | Edwards Lifesciences Corporation | $7,251 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-04-03 | Edwards Lifesciences Corporation | $5,974 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2025 | |
| 2025-04-03 | Edwards Lifesciences Corporation | $3,205 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-04-02 | Alnylam Pharmaceuticals Inc. | $13,638 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-04-02 | Alnylam Pharmaceuticals Inc. | $1,113 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-04-01 | Abbott Laboratories | $2,720 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-04-01 | Abbott Laboratories | $2,720 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-03-20 | Gilead Sciences, Inc. | $1,100 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2025 |
| 2025-03-19 | Edwards Lifesciences Corporation | $3,415 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2025 | |
| 2025-03-17 | Abbott Laboratories | $3,014 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-02-26 | Abbott Laboratories | $28,760 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-02-24 | GENZYME CORPORATION | $30,271 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-02-24 | GENZYME CORPORATION | $16,781 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-02-24 | GENZYME CORPORATION | $13,676 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-02-21 | Abbott Laboratories | $30,250 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | NCT06999356 --- Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitor | 2025 |
| 2025-02-21 | Biogen, Inc. | $3,000 | Research payment | Cash or cash equivalent | ADUHELM Biological, Neurology | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2025 |
| 2025-02-11 | Eli Lilly and Company | $105,655 | Research payment | Cash or cash equivalent | AMYVID Drug, Neuroscience | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
| 2025-02-11 | E.R. Squibb & Sons, L.L.C. | $495 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carc | 2025 |
| 2025-01-27 | Eli Lilly and Company | $7,204 | Research payment | In-kind items and services | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 | |
| 2025-01-22 | ModernaTX, Inc. | $3,912 | Research payment | Cash or cash equivalent | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants | 2025 | |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | $1,458 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resecti | 2025 |
| 2025-01-20 | Edwards Lifesciences Corporation | $25,384 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-01-17 | E.R. Squibb & Sons, L.L.C. | $10,584 | Research payment | Cash or cash equivalent | OPDUALAG Drug, Oncology | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination | 2025 |
| 2025-01-09 | Eli Lilly and Company | $561 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 | |
| 2025-01-08 | Biogen, Inc. | $8,671 | Research payment | Cash or cash equivalent | QALSODY Drug, ALS | A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismuta | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments